<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vivanza Biosciences Ltd has submitted a confirmation to BSE stating that the company does not qualify as a 'Large Corporate' under SEBI guidelines as of March 31, 2026. As a result, the company is not required to file the Initial Disclosure under Annexure A or Annexure XII A of the SEBI operational circulars. This is a routine compliance filing confirming the company's exempt status from enhanced disclosure norms applicable to large corporates raising debt. The company has provided this confirmation for the financial year ended March 31, 2026.
This filing has no direct impact on shareholders or stock price. It simply confirms that Vivanza Biosciences is a smaller entity that does not meet the thresholds for Large Corporate classification, meaning it has lower exposure to or involvement in debt capital markets requiring enhanced SEBI disclosures.